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Figure 1. Heat map analysis of microarray data. Normal, OA and MCP-1 treated
sMPC mRNA was analyzed using microarrays. A heat map demonstrates that normal
and OA sMPCs display very distinct expression patterns, while normal sMPCs treated
with MCP-1 take on an expression proﬁle similar to OA sMPCs (A). Color range signiﬁes
either up regulation (red), down regulation (blue), no signiﬁcant difference (yellow) in
gene expression between samples).
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MONOCYTE CHEMOTACTIC PROTEIN-1 REGULATES THE
CHONDROGENIC ACTIVITY OF SYNOVIAL MESENCHYMAL
PROGENITOR CELLS
Q. Harris, J. Seto, K. O'Biren, P. Lee, C. Kondo, B. Heard, D. Hart, R.J.
Krawetz. Univ. of Calgary, Calgary, AB, Canada
Purpose: Osteoarthritis (OA) is a multifactorial, often progressive,
painful disease that often progresses with the apparently irreversible
loss of articular cartilage, exposing underlying bone, resulting in pain
and loss of mobility. This cartilage loss is thought to be permanent
due to ineffective repair, and apparent lack of stem/progenitor cells in
that tissue. However, the adjacent synovial lining and synovial ﬂuid
are abundant with mesenchymal progenitor/stem cells (sMPCs)
capable of differentiating into cartilage both in vitro and in vivo, but it
remains unknown if these cells play an active role in cartilage repair.
Previous studies have demonstrated that MPCs can home to factors
such as monocyte chemotactic protein 1 (MCP-1/CCL2) expressed
after injury. However, the role of MCP-1 in the recruitment and
retention of stem/progenitor cells to a site of injury or chronic disease
(such as OA) is not fully understood which makes the elucidation of
its roles in OA and stem cell biology in general particularly inter-
esting. In the current study, we present evidence suggesting that
MCP-1 is up regulated in the synovial ﬂuid of patients with OA and
exposure to this molecule triggers changes in sMPC transcriptional
regulation, leading to a loss of chondrogenic potential in this cell
population.
Methods: Knee synovial ﬂuid was aspirated from normal individuals
(n¼10) and patients with OA (n¼10). The inﬂammatory proﬁle of the
ﬂuid was analyzed using Luminex Multiplex Assays for 65 distinct
cytokines and chemokines. sMPCs were derived from fresh synovial
ﬂuid (normal and OA) by aspiration and centrifugation. After 7-14
days in culture, colonies were observed and the cells were sorted
using FACS for the CD105+, CD90+, CD73+, CD45-, CD11b-population.
Chondrogenesis of sMPCs was evaluated in each of the treatment
groups by quantifying the relative gene and protein expression of the
chondrogenic markers Sox9, Collagen2, and Aggrecan using quanti-
tative polymerase chain reaction (qPCR) and Western blot analysis.
Microarray analysis was performed using the Affymetrix GeneChip
Human Gene 1.0 ST and the data was examined using GeneSpring
software.
Results: MCP-1 is up-regulated in OA synovial ﬂuid compared to
normal samples and exposure to physiological (OA knee joint synovial
ﬂuid) levels of MCP-1 activates sMPCs (increasing telomerase activity),
while concurrently inhibiting these cells from undergoing chondro-
genesis (at the gene, protein, and primitive tissue levels). Furthermore,
exposure to physiological levels of MCP-1 triggers changes in the
transcriptome of sMPCs (Figure 1) and prolonged exposure to the
chemokine induces the expression of MCP-1 in sMPCs, resulting in
a positive feedback loop from which sMPCs cannot apparently escape
(Figure 2).
Conclusions: We have demonstrated that MCP-1 can signiﬁcantly
regulate the chondrogenic potential and telomerase activity of
human synovial MPCs possibly through modiﬁcation of the tran-
scriptional network within the cells. Understanding the mechanism
by which MCP-1 ‘re-programs’ these sMPCs may lead to novelFigure 2. Schematic diagram of the potential role of MCP-1 in endogenous cartilage rep
assistance from local sMPCs. After injury to the cartilage surface macrophages secrete fact
initiating chondrogenesis and effecting repair, while simultaneously increasing the prolifera
MCP-1 which ‘locks’ the joint in a viscous cycle of ineffective repair.pharmaceutical targets and interventions in OA possibly through
‘short circuiting’ the vicious cycle that appears to be activated by
this chemokine within the joint environment after the onset of
injury/OA.
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